189 related articles for article (PubMed ID: 35531590)
1. Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer.
Jain S; Nadeem N; Ulfenborg B; Mäkelä M; Ruma SA; Terävä J; Huhtinen K; Leivo J; Kristjansdottir B; Pettersson K; Sundfeldt K; Gidwani K
Int J Cancer; 2022 Oct; 151(7):1175-1184. PubMed ID: 35531590
[TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125).
Chauhan SC; Singh AP; Ruiz F; Johansson SL; Jain M; Smith LM; Moniaux N; Batra SK
Mod Pathol; 2006 Oct; 19(10):1386-94. PubMed ID: 16880776
[TBL] [Abstract][Full Text] [Related]
3. Mucins MUC16 and MUC1 are major carriers of SLe(a) and SLe(x) in borderline and malignant serous ovarian tumors.
Ricardo S; Marcos-Silva L; Valente C; Coelho R; Gomes R; David L
Virchows Arch; 2016 Jun; 468(6):715-22. PubMed ID: 27003157
[TBL] [Abstract][Full Text] [Related]
4. Detection of glyco-mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours.
Ricardo S; Marcos-Silva L; Pereira D; Pinto R; Almeida R; Söderberg O; Mandel U; Clausen H; Felix A; Lunet N; David L
Mol Oncol; 2015 Feb; 9(2):503-12. PubMed ID: 25454345
[TBL] [Abstract][Full Text] [Related]
5. Spectrally separated dual-label upconversion luminescence lateral flow assay for cancer-specific STn-glycosylation in CA125 and CA15-3.
Ekman M; Salminen T; Raiko K; Soukka T; Gidwani K; Martiskainen I
Anal Bioanal Chem; 2024 May; 416(13):3251-3260. PubMed ID: 38584178
[TBL] [Abstract][Full Text] [Related]
6. Europium Nanoparticle-Based Sialyl-Tn Monoclonal Antibody Discriminates Epithelial Ovarian Cancer-Associated CA125 from Benign Sources.
Gidwani K; Nadeem N; Huhtinen K; Kekki H; Heinosalo T; Hynninen J; Perheentupa A; Poutanen M; Carpen O; Pettersson K; Lamminmäki U
J Appl Lab Med; 2019 Nov; 4(3):299-310. PubMed ID: 31659068
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle-aided glycovariant assays to bridge biomarker performance and ctDNA results.
Gidwani K; Kekki H; Terävä J; Soukka T; Sundfeldt K; Pettersson K
Mol Aspects Med; 2020 Apr; 72():100831. PubMed ID: 31787337
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in relation to ovarian cancer risk and survival.
Williams KA; Terry KL; Tworoger SS; Vitonis AF; Titus LJ; Cramer DW
PLoS One; 2014; 9(2):e88334. PubMed ID: 24551091
[TBL] [Abstract][Full Text] [Related]
9. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.
Budiu RA; Mantia-Smaldone G; Elishaev E; Chu T; Thaller J; McCabe K; Lenzner D; Edwards RP; Vlad AM
Cancer Immunol Immunother; 2011 Jul; 60(7):975-84. PubMed ID: 21461842
[TBL] [Abstract][Full Text] [Related]
10. Different levels of sialyl-Tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer.
Akita K; Yoshida S; Ikehara Y; Shirakawa S; Toda M; Inoue M; Kitawaki J; Nakanishi H; Narimatsu H; Nakada H
Int J Gynecol Cancer; 2012 May; 22(4):531-8. PubMed ID: 22367369
[TBL] [Abstract][Full Text] [Related]
11. Aberrant glycosylation of α3 integrins as diagnostic markers in epithelial ovarian cancer.
Jain S; Parimelazhagan Santhi P; Vinod R; Afrin Ruma S; Huhtinen K; Pettersson K; Sundfeldt K; Leivo J; Gidwani K
Clin Chim Acta; 2023 Mar; 543():117323. PubMed ID: 37003518
[TBL] [Abstract][Full Text] [Related]
12. Microarray Glycoprofiling of CA125 improves differential diagnosis of ovarian cancer.
Chen K; Gentry-Maharaj A; Burnell M; Steentoft C; Marcos-Silva L; Mandel U; Jacobs I; Dawnay A; Menon U; Blixt O
J Proteome Res; 2013 Mar; 12(3):1408-18. PubMed ID: 23360124
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
[TBL] [Abstract][Full Text] [Related]
14. Puerperal mastitis: a reproductive event of importance affecting anti-mucin antibody levels and ovarian cancer risk.
Cramer DW; Williams K; Vitonis AF; Yamamoto HS; Stuebe A; Welch WR; Titus L; Fichorova RN
Cancer Causes Control; 2013 Nov; 24(11):1911-23. PubMed ID: 23925696
[TBL] [Abstract][Full Text] [Related]
15. Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma.
Terävä J; Tiainen L; Lamminmäki U; Kellokumpu-Lehtinen PL; Pettersson K; Gidwani K
PLoS One; 2019; 14(7):e0219480. PubMed ID: 31344060
[TBL] [Abstract][Full Text] [Related]
16. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.
Felder M; Kapur A; Gonzalez-Bosquet J; Horibata S; Heintz J; Albrecht R; Fass L; Kaur J; Hu K; Shojaei H; Whelan RJ; Patankar MS
Mol Cancer; 2014 May; 13():129. PubMed ID: 24886523
[TBL] [Abstract][Full Text] [Related]
17. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
18. Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16.
Duraisamy S; Ramasamy S; Kharbanda S; Kufe D
Gene; 2006 May; 373():28-34. PubMed ID: 16500040
[TBL] [Abstract][Full Text] [Related]
19. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.
Li W; Wang D
Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526
[TBL] [Abstract][Full Text] [Related]
20. Exploratory Analysis of CA125-MGL and -STn Glycoforms in the Differential Diagnostics of Pelvic Masses.
Salminen L; Nadeem N; Rolfsen AL; Dørum A; Laajala TD; Grènman S; Hietanen S; Heinosalo T; Perheentupa A; Poutanen M; Bolstad N; Carpén O; Lamminmäki U; Pettersson K; Gidwani K; Hynninen J; Huhtinen K
J Appl Lab Med; 2020 Mar; 5(2):263-272. PubMed ID: 32445385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
